Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 10/20 | 0.41 |
| ▸ | CA2 | P00918 | 10/20 | 0.41 |
| ▸ | CA9 | Q16790 | 8/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 5/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 6/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4745003 | 0.87 | SYK (0.44) | NPSR1CA1CA2CA9CA13 | |
| SCHEMBL8383001 | 0.82 | NPSR1 (0.44) | NPSR1ALDH1A1MAPTRXFP1 | |
| SCHEMBL4787733 | 0.81 | FOS (0.41) | NPSR1 | |
| SCHEMBL8384543 | 0.81 | NPSR1 (0.53) | NPSR1ALDH1A1MAPTRXFP1 | |
| SCHEMBL7898133 | 0.80 | CA9 (0.40) | CA1CA2CA9CA13CA12 | |
| SCHEMBL4748211 | 0.79 | NPSR1 (0.41) | NPSR1CA1CA2CA9CA12 | |
| SCHEMBL4744572 | 0.72 | MAPT (0.55) | NPSR1ALDH1A1MAPTRXFP1 | |
| SCHEMBL4747831 | 0.71 | NPSR1 (0.51) | NPSR1ALDH1A1MAPTRXFP1 | |
| SCHEMBL7892682 | 0.70 | SYK (0.44) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL4744573 | 0.70 | CYP1A2 (0.57) | NPSR1ALDH1A1MAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008110891-A2 | NEW HETEROCYCLIC COMPOUNDS | ORCHID RESEARCH LABORATORIES LIMITED, (IN) | 2008-09-18 | — | — | WO | claimed |
| US-20080221103-A1 | New heterocyclic compounds | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2008-09-11 | — | — | US | claimed |
| WO-2008110891-A2 | NEW HETEROCYCLIC COMPOUNDS | ORCHID RESEARCH LABORATORIES LIMITED, (IN) | 2008-09-18 | — | — | WO | disclosed |
| US-20080221103-A1 | New heterocyclic compounds | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221103-A1 | New heterocyclic compounds | LOXL4, CXCR4, LTC4S | NPSR1 992/4885CA1 1344/4885CA2 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.